The purpose of this study was to determine whether women with breast cancer and the presence of the drug tamoxifen, are more severely depressed than women with breast cancer and the absence of tamoxifen. Average Beck Depression Inventory (BDI) scores did not differ between the two sub-groups; however, two significant group differences were found. First, 10 women in the tamoxifen group had scores of zero (versus 4 in the absence of prescribed tamoxifen group). Research has shown that scores of zero do not always reflect an absence of depression. Second, the most severely depressed women (BDI scores in the 25 to 31 range) were also members of the tamoxifen group. These results suggest that for the women taking tamoxifen at the time of the study, a history of depression was associated with more severe depressive symptoms. Finally, among women without tamoxifen, several had discontinued tamoxifen therapy because of depressive side effects.
","abstract_html":"<p>The purpose of this study was to determine whether women with breast cancer and the presence of the drug tamoxifen, are more severely depressed than women with breast cancer and the absence of tamoxifen. Average Beck Depression Inventory (BDI) scores did not differ between the two sub-groups; however, two significant group differences were found. First, 10 women in the tamoxifen group had scores of zero (versus 4 in the absence of prescribed tamoxifen group). Research has shown that scores of zero do not always reflect an absence of depression. Second, the most severely depressed women (BDI scores in the 25 to 31 range) were also members of the tamoxifen group. These results suggest that for the women taking tamoxifen at the time of the study, a history of depression was associated with more severe depressive symptoms. Finally, among women without tamoxifen, several had discontinued tamoxifen therapy because of depressive side effects.</p>","abstract_has_math":false,"creators":["Lynn, Terry Marie"],"institution":null,"degree_name":"Master of Social Work (MSW)","degree_level":"Thesis","degree_discipline":"Social Work","degree_department":null,"school":null,"contributors":["Mark G. Haviland","Dianna J. Simon","Craig R. Jackson"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":1998,"date_issued":"1998-06-01T07:00:00Z","date_published":"1998-06-01T07:00:00Z","updated_at":"2026-07-24T02:54:10Z","subjects":["Chemicals and Drugs","Neoplasms","Social Work","Women's Health","Tamoxifen -- adverse effects; Depression -- chemically-induced; Breast Neoplasms -- drug therapy"],"languages":["English"],"rights":["This title appears here courtesy of the author, who has granted Loma Linda University a limited, non-exclusive right to make this publication available to the public. The author retains all other copyrights."],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://scholarsrepository.llu.edu/etd/1105","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Mark G. Haviland","Dianna J. Simon","Craig R. Jackson"]},{"key":"dc:creator","label":"Author","values":["Lynn, Terry Marie"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"thesis:degree_discipline","label":"Discipline","values":["Social Work"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Social Work (MSW)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Chemicals and Drugs","Neoplasms","Social Work","Women's Health","Tamoxifen -- adverse effects; Depression -- chemically-induced; Breast Neoplasms -- drug therapy"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]},{"key":"dc:rights","label":"Dc Rights","values":["This title appears here courtesy of the author, who has granted Loma Linda University a limited, non-exclusive right to make this publication available to the public. The author retains all other copyrights."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://scholarsrepository.llu.edu/etd/1105"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The purpose of this study was to determine whether women with breast cancer and the presence of the drug tamoxifen, are more severely depressed than women with breast cancer and the absence of tamoxifen. Average Beck Depression Inventory (BDI) scores did not differ between the two sub-groups; however, two significant group differences were found. First, 10 women in the tamoxifen group had scores of zero (versus 4 in the absence of prescribed tamoxifen group). Research has shown that scores of zero do not always reflect an absence of depression. Second, the most severely depressed women (BDI scores in the 25 to 31 range) were also members of the tamoxifen group. These results suggest that for the women taking tamoxifen at the time of the study, a history of depression was associated with more severe depressive symptoms. Finally, among women without tamoxifen, several had discontinued tamoxifen therapy because of depressive side effects.
"]},{"key":"dc:title","label":"Title","values":["The Relationship between Tamoxifen and Depressive Symptoms in Women with Breast Cancer"]}]}],"canonical_facts":{"dc:contributor":["Mark G. Haviland","Dianna J. Simon","Craig R. Jackson"],"dc:creator":["Lynn, Terry Marie"],"dc:description.abstract":["The purpose of this study was to determine whether women with breast cancer and the presence of the drug tamoxifen, are more severely depressed than women with breast cancer and the absence of tamoxifen. Average Beck Depression Inventory (BDI) scores did not differ between the two sub-groups; however, two significant group differences were found. First, 10 women in the tamoxifen group had scores of zero (versus 4 in the absence of prescribed tamoxifen group). Research has shown that scores of zero do not always reflect an absence of depression. Second, the most severely depressed women (BDI scores in the 25 to 31 range) were also members of the tamoxifen group. These results suggest that for the women taking tamoxifen at the time of the study, a history of depression was associated with more severe depressive symptoms. Finally, among women without tamoxifen, several had discontinued tamoxifen therapy because of depressive side effects.
"],"dc:identifier":["https://scholarsrepository.llu.edu/etd/1105"],"dc:language":["English"],"dc:rights":["This title appears here courtesy of the author, who has granted Loma Linda University a limited, non-exclusive right to make this publication available to the public. The author retains all other copyrights."],"dc:subject":["Chemicals and Drugs","Neoplasms","Social Work","Women's Health","Tamoxifen -- adverse effects; Depression -- chemically-induced; Breast Neoplasms -- drug therapy"],"dc:title":["The Relationship between Tamoxifen and Depressive Symptoms in Women with Breast Cancer"],"thesis:degree_discipline":["Social Work"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Master of Social Work (MSW)"]},"updated_at":"2026-07-24T02:54:10Z"}